China

With biosimilar threat under control (for now), Roche savors demand for its new drugs
With biosimilar threat under control (for now), Roche savors demand for its new drugs
Endpoints
Roche
M&A
Spark Therapeutics
China
Flag link:
Flow of US biotech VC dollars on track to match record 2018 levels — China? Not so much
Flow of US biotech VC dollars on track to match record 2018 levels — China? Not so much
Endpoints
biotech
venture capital
China
Flag link:
Merck’s KEYTRUDA approved as monotherapy in China for first-line treatment of certain patients with advanced NSCLC
Merck’s KEYTRUDA approved as monotherapy in China for first-line treatment of certain patients with advanced NSCLC
Pharmaceutical Business Review
Merck
Keytruda
China
non-small cell lung cancer
Flag link:
Could the U.S.-China trade war stifle medical device innovation?
Could the U.S.-China trade war stifle medical device innovation?
Mass Device
China
trade war
trade
devices
R&D
Flag link:
Sanofi, AZ, Lilly and more win business in China's expanded cut-price purchase program
Sanofi, AZ, Lilly and more win business in China's expanded cut-price purchase program
Fierce Pharma
China
Sanofi
AstraZeneca
Eli Lilly
drug pricing
Flag link:
Couple stole trade secrets from U.S. children’s hospital to market their Chinese biotech, prosecutors say
Couple stole trade secrets from U.S. children’s hospital to market their Chinese biotech, prosecutors say
Stat
China
trade secrets
Flag link:
AZ gets China nod for Tagrisso in first-line lung cancer
AZ gets China nod for Tagrisso in first-line lung cancer
Pharmaforum
AstraZeneca
China
Tagrisso
non-small cell lung cancer
Flag link:
China expands drug bulk-buy program, puts pressure on pharma firms
China expands drug bulk-buy program, puts pressure on pharma firms
Yahoo/Reuters
China
bulk buying
Flag link:
BeiGene's first U.S. NDA tests global development strategy
BeiGene's first U.S. NDA tests global development strategy
BioCentury
BeiGene
China
FDA
drug development
zanubrutinib
Flag link:
AstraZeneca's Kidney Drug Roxadustat Gets Second Nod in China
AstraZeneca's Kidney Drug Roxadustat Gets Second Nod in China
Yahoo/Zacks.com
AstraZeneca
FibroGen
China
roxadustat
chronic kidney disease
Flag link:
Biomedical stakeholders caution against limiting U.S.-China collaboration
Biomedical stakeholders caution against limiting U.S.-China collaboration
BioCentury
China
R&D
Flag link:
Is Pfizer's established drugs' decline in China the ‘canary in the coalmine?’
Is Pfizer's established drugs' decline in China the ‘canary in the coalmine?’
Fierce Pharma
Pfizer
Upjohn
China
Flag link:
China has become a CEO-level priority for multinational pharmaceutical companies: the trend and the implications
China has become a CEO-level priority for multinational pharmaceutical companies: the trend and the implications
Endpoints
China
pharma industry
Flag link:
These 7 trends matter the most for medtech in 2019
These 7 trends matter the most for medtech in 2019
Mass Device
China
robotic surgery
devices
Stryker
Medtronic
FDA
Intuitive Surgical
Flag link:
AstraZeneca raises sales forecast after second-quarter cancer drug, China boost
AstraZeneca raises sales forecast after second-quarter cancer drug, China boost
Yahoo/Reuters
AstraZeneca
earnings
China
Flag link:
Novartis multiple sclerosis product Gilenya approved in China
Novartis multiple sclerosis product Gilenya approved in China
Pharmaceutical Business Review
China
Novartis
multiple sclerosis
Gilenya
Flag link:
HitGen joins growing Shanghai IPO queue
HitGen joins growing Shanghai IPO queue
BioCentury
HitGen
IPOs
China
Shanghai
Flag link:
Megadeals Enter Biotech Realm — And 3 Other Trends To Watch In 2019
Megadeals Enter Biotech Realm — And 3 Other Trends To Watch In 2019
Investors Business Daily
biotech
M&A
China
Flag link:
Trade tensions are impeding the flow of Chinese money to US biotechs — but how much?
Trade tensions are impeding the flow of Chinese money to US biotechs — but how much?
Endpoints
China
venture capital
biotech
trade
Flag link:
Zai builds cancer combo strategy with rights to Incyte's PD-1 mAb
Zai builds cancer combo strategy with rights to Incyte's PD-1 mAb
BioCentury
Zai Lab
China
PD-1 inhibitors
Incyte
Flag link:

Pages